Rakuten Investment Management Inc. Purchases 12,950 Shares of IDEXX Laboratories, Inc. $IDXX

Rakuten Investment Management Inc. increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 692.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,821 shares of the company’s stock after acquiring an additional 12,950 shares during the period. Rakuten Investment Management Inc.’s holdings in IDEXX Laboratories were worth $10,195,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. L2 Asset Management LLC grew its holdings in shares of IDEXX Laboratories by 6.7% in the fourth quarter. L2 Asset Management LLC now owns 399 shares of the company’s stock worth $270,000 after acquiring an additional 25 shares during the period. 71 West Capital Partners bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth $633,000. Faithward Advisors LLC grew its holdings in shares of IDEXX Laboratories by 2.6% in the fourth quarter. Faithward Advisors LLC now owns 5,910 shares of the company’s stock worth $3,998,000 after acquiring an additional 149 shares during the period. Sienna Gestion bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth $1,454,000. Finally, Silvant Capital Management LLC grew its holdings in shares of IDEXX Laboratories by 17.3% in the fourth quarter. Silvant Capital Management LLC now owns 13,035 shares of the company’s stock worth $8,819,000 after acquiring an additional 1,918 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. UBS Group lowered their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Citigroup assumed coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $573.00 on Wednesday. The stock’s 50-day simple moving average is $563.14 and its 200-day simple moving average is $624.14. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98. The company has a market capitalization of $45.20 billion, a price-to-earnings ratio of 42.19, a PEG ratio of 3.12 and a beta of 1.55. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the business earned $2.91 earnings per share. The business’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.